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The focus ofthe 26th Bethesda ~(~n~c~cnce is the athlete with 
an identiticd cardiovascular abnormality, and its goal is 10 
dew&p prudent consensus rccommcndations regarding the 
eligibility of such rtthlctes for camp&ion in a sport. Thcrc- 
fore, this document constitutes an updating of the !6th Be- 
t a Conference (I) in which formel rccommcndation:; were 
first published in t985. To again accomplish this objective, we 
have attempted to ascertain by way of consensus which cardio- 
vascular abnormalities, and with what degree of severity, would 
place the competitive athlete at increased risk for sudden 
death or disease progression, thereby justifying a medical 
recommendation against participation in certain sports. 
asons for revising the 16th Bcthcsda 
Conference. First, many advances have been made in the 
diagnosis, treatment and understanding of cardiovascular dis- 
eases over the past decade. Second, the interest in sudden 
cardiac death in competitive athletes has intensified and 
beczme a highly visible and compelling issue because of 
catastrophes involving well known, elite collegiate and profcs- 
sional athletes (3-4). Such events have also educated us with 
respect to many of the ethicat, legal and pnctical issues that 
mazy affect medical decision making in such athletes, serving as 
an additional stimulus to upgrade tbs original Bethesda Con- 
ference on this topic. Third, the previous recommendations 
were read largely by cardiologists and not necessarily by those 
physicians who routinely assess competitive athletes (5). 
Therefore, to ensure wider distribution f these recommenda- 
tions, they are being published simultaneously in theJounralof 
tjle American Co oj’Curdioiqy and in Medicine and Scicw 
in Spwts and Euwise. 
As before, we have defined the competitive athlete as one 
who participates in an organized team or individual sport that 
requires regular competition against others as a central com- 
ponent, places a high premium on excellence and achievement 
and requires some form of systematic training (6). An impor- 
tant facet in dclining ii compctitivc activity is ~v~l~t~~~~ the 
athlctc is able to MC proper j~ld~~~c~it in ~isscssing when to 
appr(~~rii~tely cxtricatc hims&’ (or herself) from the event, 
should that become nceess:iry. For cxamplo, li~hthcedcdncss. 
fatigue or chest discomfort, or imy other potential warning 
symptoms of ~it~~il)Vi~S~~ti~r diSWW ocw-ring lillring CWllpC- 
titian, may be ditlicult for the athlete to rcliahly 
from the normal sensations of intcnsc physical activity itself. It 
is also worth noting that brcausc of the unique circumstances 
and pressures of organized athletic c~~mpetiti~~, ao athlete is 
not likely to terminate physical cxcrtion CVUI ~4~91 the medical 
need to do so may be rccognizcd. 
Athlctcs may he regarded ;IS competitive regardless of age 
or level of p;irIicipation, which includes youth, ioterscholastic, 
intcrc~~llc~~~~tc, r(~fcssi~~~~i~l or masters ports. The rccommcn- 
dations of this Confcrencc arc not formulated for the pwly 
IWrciitimlal ilthlCtL!, nor do tbcy pc‘rtilin to pirrticipation in 
cardiac rehabilitation programs. Nowevcr. WC’ do recognize the 
likelihood that some practitioners will choose to utilize thcsc 
recommendations for rccrentional athlctcs participat~og out- 
side the arena of competitive athlcticz (as strictly defined 
here), as well as nonathletcs whose employment requires 
particularly vigorous and intense activity, such as firemen or 
emergency medical technicians. This process will require mak- 
ing certain judgments and extrapolations to account for per- 
ceived differences in the intensity of training between compet- 
itive athletes and other such physically active persons. 
However, we should emphasize that the prevalence of 
cardiovascular disease in a young athletic population is low, 
and although the precise risk of sudden cardiac death in 
athletes with underlying disease is unknown, it is undoubtedly 
low. Indeed, the number of competitive athletes who die 
prematurely every year is small, particularly when considered 
in light of the large number of athletes of all ages competing in 
a wide spectrum of sporting activities. At least 5 million young 
people are actively engaged in competitive athletics in the 
United States at the high school, collegiate and professional 
levels, not even including those in youth, junior high school or 
masters athletic programs. 
If sudden cardiac death in athletes is an uncommon event, 
why, then, should we perceive it to be a medical issue of 
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isndations may (~cc~~si(~l~~~l~y cause some atblctcs to 
w from corn~ct~t~(~~ ~fl~eccss~~r~ly~ This, of course, 
e unfortunate because athletes may derive from these 
activities considerable self-assurance, confidence and physical 
well-being, as well as financial security. 
It should also be emphasized that the recommendations for 
permissible levels of activity formulated in this document are 
as inllexible or absolutely restrictive. A physician with signiti- 
cant knowledge about the severity of an athlete’s cardiovascu- 
lar abnormality, psychologic response to competition and other 
medically relevant factors may in fact choose to liberalize these 
recommendations in selected instances. 
Nevertheless, the primary impetus and justification for this 
26th Bethesda Conference is the generally accepted medical 
perception that athletes with certain cardiovascular abnormal- 
ities are at an increased risk for sudden cardiac death or more 
rapid disease progression (compared with other athletes free 
of cardiovascular disease) by virtue of their exposure to the 
physiologic and psychologic stress of intense training and 
competition. A!though it was possible in some instances for the 
participants of this conference to make recommendations that 
reflected a stratification of risk for certain diseases, often it 
was difficult to reliably ascertain the precise degree to which 
this perceived risk is increased. The 26th Bethesda Conference 
recommendations are necessarily based largely on our individ- 
ual and collective judgment and experience, as well as on the 
pertinent scientific data that are available. Indeed, in this 
process of formulating consensus recommendations, confer- 
ence participants, who are cardiovascular authorities most 
comfortable with a high level of precision, were often required 
to confront areas in which there was a qaucity of relevant 
“hard” data. Each of the six task force reports had designated 
authors, but all me bers of the conference contri 
of each task force document. 
competitive sports do not involve 
of exercise and have attempted a 
ee Classification of Sports). For 
istance running obviously differs 
s~bsta~tia~~y from golfing or bowling. ndeed, some youth 
sports, al gh co Live, often do not r 
intensity t (i.e., h baseball;. Even wi 
team sport, there may be important variability i 
physical effort required at different positi 
ever, it is often extremely 
Fences in exercise int 
titudes among indivi 
the tri~inil~g demands made on those atb 
coaches. Ncvertheiess, it should bc cmpha 
petitive sports do, in fact, place the athlete 
on occasion in extreme and unusual environmental conditions 
that may be associated with alterations in blood volume, 
~~y~lr~~tii~~l and electrolytes, which in turn can cl~ba~ce t 
for potentially lethal ar~bytbmias and sudden cardiac d 
the presence of certain cardiovascular abnormalities. 
articipants in this 26th ethesda Conference are also well 
aware of the issues that may potentially a 
credibility and application of the reco 
pertinent segments of the medicai and sports communities. 
For example, what, in fa , is the appropriate doctor-patient 
(at~~~ctc) relati(~nsb~p, an what arc the ethical obligations in 
these circumstances? Who is the “gatekeeper” responsible for 
deciding whether an athlete with a cardiovascular abnormality 
is eligible to compete in a sport? What are the respective roles 
of the team and consulting physician, athlete and family, school 
or profession;r team, league or athletic governing body, and 
what are :IIC proper lines of authority? Indeed, these condi- 
tions were addressed in great detail at the onset of the 
Conference in a panel discussion (see Ethical, Legal and 
Practical Considerations Affecting Medical Decision-Making 
in Competitive Athletes), and the major points raised in that 
intensive discussion are summarized herein. Thus, the present 
Bethesda Conference extends well beyond that of the previous 
publication (I). 
The Conference also acknowledges the potential impor- 
tance of gender and race in making eligibility recommenda- 
tions. Since the 16th Bethesda Conference, women have made 
substantial advances in achieving equal participation opportu- 
nities and status with men at all levels of competition. This 
process has been accompanied by an increased number of 
female competitors (now about one-third of all athletes in 
interscholastic and intercollegiate sports) who are training at 
increasingly intensive levels. At present, however, only a 
minority of sudden cardiac deaths have involved women 
athletes. African-Americans comprise a large segment of the 
athletic population in many sports; concomitant with that hi& 
level of participation has come a considerable proportion of 
sudden cardiac deaths (7). 
It is important o define what issues are and are not 
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&dressed in the formulation f this Bethesda Conference. For 
wple, the Conference develops recommendations f r the 
eligl>ility of competitive athletes already known to have a 
cardiovascular abnormality or disease. In other words, given 
the presence of a cardiovascular abnormality in a trained 
athlete, what is the most appropriate and prudent course of 
action with regard to athletic competition? However, although 
of great importance, the complex issues urrounding prepar- 
tic&don screening for cardiovascular disease were judged to 
be beyond the scope of this particular Conference. Also not 
included, because of space constraints, are detailed escrip- 
tions of the clinical methods and criteria by which each 
congenital oracquired cardiovascular lesion may be reliably 
identified ina given athlete. Finally, the Conference does not 
address the mannrgement of athletes with cardiovascular dis- 
ease in the period after their disqualification from competitive 
sports, uch as the selection ofalternative physical ctivities. 
We have focused largely on those cardiovascular diseases 
that are acknowledged or potential causes of sudden death in 
athletes, the majority of which occur on the athletic field 
(7-13). The most common to be implicated inyoung athletes 
(7,8) are hypertrophic cardiomyopathy, congenital nomalies 
of the coronary arteries, Marfan syndrome, myocarditis and 
arrhythmogenic right ventricular dysplasia n one series (9); 
sudden death in older athletes i due, in the vast majority of 
instances, to coronary artery disease (IO-13). However, we 
have arbitrarily excluded from consideration ther potential 
causes of sudden death in athletes, uch as heat stroke, 
bronchial sthma or other pulmonary diseases, cerebral hem- 
orrhage or sickle cell trait (14) or other hematologic disorders. 
This Conference largely excluded from consideration debates 
regarding drug testing and the effects that drug abuse (i.e., 
cocaine and anabolic steroids) may have on cardiovascular 
structure and function, or as a risk factor for sudden cardiac 
death in athletes with or without underlying cardiovascular 
disease. In particular, cocaine, which causes marked coronary 
vasospasm and decreased myocardial oxygen supply (15), may 
be particularly harmful during sports with high myocardial 
oxygen demands. We clearly recognize the not uncommon 
usage of such drugs in certain athletic populations, the poten- 
tial adverse impact that hese agents may have on the cardio- 
vascu!ar system ofcompetitive athletes and also the long-term 
etfects, which can mimic that of other pathologic conditions. 
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Within the framework of the acknowledged strengths and 
unavoidable limitations, we believe that he recommendations 
of the 26th Bethesda Conference will be of value to the team 
physician or consulting specialist (and to other involved par- 
ties) who make decisions concerning eligibility for competition 
in athletes with identified cardiovascular abnormalities, partic- 
ularly at a time when these processes have come under intense 
public scrutiny. 
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